- Coordinator
- Weizmann Institute of Science, Israel
- Runs
- 1 August 2026 to 31 January 2028
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101335588
What the project is doing
In the project's own words, from its summary on CORDIS.
Immunotherapy has transformed cancer treatment, yet many patients fail to benefit because their tumors develop intrinsic mechanisms to block immune attack. Recent discoveries from our ERC-funded work revealed that the proteasome, a central protein degradation system, can be hijacked by tumors to suppress immune recognition and promote an immunosuppressive environment. This Proof of Concept project aims to translate these findings into a novel therapeutic approach.
We will develop and validate small molecules that block this tumor-associated mechanism, restoring the ability of the immune system to detect and eliminate cancer cells. Our focus will be on two major cancers with a high unmet need, non–small cell lung cancer and aggressive breast cancer, where resistance to immunotherapy remains a critical challenge. The project will combine the development of a small molecule which will allow us to modulate proteasomes activity, together with preclinical validation, and a commercialization pathway including intellectual property protection and market analysis.
By the end of the project, we expect to deliver optimized drug candidates and a biomarker-guided framework to identify patients most likely to benefit. Ultimately, this work seeks to establish a new therapeutic class that enhances the effectiveness of existing immunotherapies, with the long-term goal of improving outcomes for patients whose cancers currently remain resistant to treatment.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Weizmann Institute of Science | Rehovot | Israel | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI